NASDAQ:SMFR - Nasdaq - US81663L1017 - Common Stock - Currency: USD
0.3106
+0.07 (+26.78%)
The current stock price of SMFR is 0.3106 USD. In the past month the price increased by 1.94%. In the past year, price decreased by -92.31%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 10.89 | 81.54B | ||
CVS | CVS HEALTH CORP | 11.73 | 80.01B | ||
LH | LABCORP HOLDINGS INC | 17.27 | 20.98B | ||
DGX | QUEST DIAGNOSTICS INC | 19.35 | 19.38B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.74 | 13.54B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 148.77 | 12.18B | ||
DVA | DAVITA INC | 15.07 | 11.74B | ||
HIMS | HIMS & HERS HEALTH INC | 100.17 | 9.63B | ||
CHE | CHEMED CORP | 23.85 | 8.18B | ||
CRVL | CORVEL CORP | 25.76 | 5.53B | ||
OPCH | OPTION CARE HEALTH INC | 26.85 | 5.44B | ||
GH | GUARDANT HEALTH INC | N/A | 5.37B |
Sema4 Holdings Corp.is a patient centered health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,200 full-time employees. The company went IPO on 2020-09-04. The firm applies artificial intelligence and machine learning to clinical and genomic data to build models of human health and define individualized health trajectories. The Company’s health intelligence platform, Centrellis enables users to generate a complete understanding of disease and wellness and to provide science-driven solutions to pressing medical needs. Its Expanded Carrier Screen (ECS) is a carrier screen for inherited conditions. Its Noninvasive Prenatal Testing Solutions is a test that screens for autosomal and sex chromosome aneuploidies. Its Natalis Newborn Screening Solutions is a test of its screening portfolio allowing for detection of heritable conditions from pre-conception, pregnancy and childhood. The firm also includes Signal Precision Oncology Solutions.
SEMA4 HOLDINGS CORP
333 Ludlow Street, North Tower, 8Th Floor
Stamford CONNECTICUT US
CEO: Eli D. Casdin
Employees: 1200
Company Website: https://sema4.com/
Phone: 16177808742.0
The current stock price of SMFR is 0.3106 USD. The price increased by 26.78% in the last trading session.
The exchange symbol of SEMA4 HOLDINGS CORP is SMFR and it is listed on the Nasdaq exchange.
SMFR stock is listed on the Nasdaq exchange.
10 analysts have analysed SMFR and the average price target is 1.79 USD. This implies a price increase of 474.69% is expected in the next year compared to the current price of 0.3106. Check the SEMA4 HOLDINGS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEMA4 HOLDINGS CORP (SMFR) has a market capitalization of 118.47M USD. This makes SMFR a Micro Cap stock.
SEMA4 HOLDINGS CORP (SMFR) currently has 1200 employees.
The Revenue of SEMA4 HOLDINGS CORP (SMFR) is expected to grow by 19.89% in the next year. Check the estimates tab for more information on the SMFR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SMFR does not pay a dividend.
SEMA4 HOLDINGS CORP (SMFR) will report earnings on 2023-03-13.
SEMA4 HOLDINGS CORP (SMFR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).
ChartMill assigns a technical rating of 1 / 10 to SMFR. When comparing the yearly performance of all stocks, SMFR is a bad performer in the overall market: 98.84% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SMFR. Both the profitability and financial health of SMFR have multiple concerns.
Over the last trailing twelve months SMFR reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 32.61% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0.1 |
ChartMill assigns a Buy % Consensus number of 80% to SMFR. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 14.52% and a revenue growth 19.89% for SMFR